PRESS RELEASE. The Swedish biotechnology company Synartro, which is developing a novel, improved treatment for knee osteoarthritis, has successfully raised SEK 34 million with Sciety and its investment syndicate. The new capital will be used for the company’s first clinical trial expected to start in 2022. ”We greatly appreciate the
PRESS RELEASE. The Swedish diagnostics company SAGA Diagnostics, which develops ultrasensitive liquid biopsy tests for early detection of cancer relapse and personalized cancer treatment, recently completed a share issue of SEK 106 million led by Segulah Medical Acceleration together with Sciety. Hadean Ventures, which invested in the company at an
NEW COMPANY AT SCIETY. Osteoarthritis affects more than 320 million people globally and is a leading source of chronic pain and disability in Europe and the US. Only half of the patients receive adequate pain relief. Sciety is now financing a company whose drug candidate has the potential to provide
EMPE Diagnostics, which has developed a rapid test for the diagnosis and resistance determination of tuberculosis, the world’s deadliest infectious disease, has recently completed a share issue of SEK 23.5 million with Sciety. The company has also received a grant of SEK 25 million from EU Horizon 2020. The new
PRESS RELEASE. Capitainer, a Swedish Medtech company that supplies intelligent solutions for self-sampling of blood and plasma, recently completed a share issue of SEK 31 million with Sciety and its investment syndicate. The investors demonstrated strong interest, and the share issue was fully subscribed in two days. The new capital
NEW COMPANY AT SCIETY. Most blood sampling is still performed by qualified healthcare personnel at care facilities, but new technology that enables simple and reliable home sampling is now changing the landscape. Sciety finances a Swedish company that is at the forefront of the technology shift. Blood sampling has an
Sciety is a capital partner specialising in life science and healthcare, offering services in capital raising and related areas. Sciety may currently have, may previously have had or may in the future be engaged by companies mentioned in our communications or operating in the sectors described, and may hold ownership interests in such companies. Sciety receives remuneration for its services, including commissions in connection to capital raises. Our communication is intended for informational purposes only and does not constitute personal investment advice. We do not guarantee the accuracy, completeness or timeliness of the information provided. Investment decisions should not be based solely on this communication.